CAMBRIDGE, Mass., March 11, 2025 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) - announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney ...

DURHAM, N.C., March 11, 2025 ( GLOBE NEWSWIRE ) -- Bioventus Inc. ( Nasdaq: BVS ) ( "Bioventus" or the "Company" ) , a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial ...

Distribution agreements recently signed for France, Turkey, Romania and Morocco ...

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of ...

WALTHAM, Mass., March 11, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.

CAMBRIDGE, Massachusetts, March 11, 2025 ( GLOBE NEWSWIRE ) -- ProMIS Neurosciences, Inc. ( Nasdaq: PMN ) , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as ...

No Stockholder Action Required at this Time No Stockholder Action Required at this Time ...

WALTHAM, Mass., March 11, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc. ( Nasdaq: DYN ) , a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to ...

First Quarter Fiscal 2025 Summary ( All comparisons are year-over-year unless otherwise noted ...

Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 ( GLOBE NEWSWIRE ) ...